February 07, 2011 AROG Pharmaceuticals, LLC (“AROG”) is pleased to announce that it has been awarded four grants under the Qualifying Therapeutic Discovery Project (QTDP) of over $829,000. AROG received the grants to advance the clinical development of its lead drug candidate, crenolanib (CP-868,596) for the following four projects: treatment of adult gliomas, pediatric gliomas, GIST, and enteric-coated tablet formulation
The QTDP program provides support through grants or a 50% tax credit for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer. The QTDP program was created by Congress on May 21, 2010 under Section 48D of the Internal Revenue Code, as enacted under the Patient Protection and Affordable Care Act.
“We are very pleased and honored to receive these grants,” said Hemanshu Shah, PhD, Chief Operating Officer of AROG. “It is recognition of the significant potential benefits that crenolanib can provide for patients with cancer.”
About Crenolanib (CP-868,596) :
Crenolanib is a potent and selective inhibitor of platelet derived growth factor receptors (PDGFR). In April 2010, AROG signed an exclusive worldwide license with Pfizer for the development and commercialization of crenolanib. Phase I single agent and Phase Ib (combination with docetaxel and axitinib) clinical trials with crenolanib have been completed.
About AROG Pharmaceutials LLC :
AROG is a private, oncology-focused drug development company based in Dallas, TX. AROG’s mission is to develop novel anticancer drugs for the treatment of rare cancers with significant unmet medical need. To learn more about AROG, pleasecontact us